HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 2,312: | Line 2,312: | ||
|- | |- | ||
|Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| || | |Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| || | ||
| | |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | ||
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | ||
| | |Pending | ||
| | | | ||
| | | | ||
|- | |- | ||
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | |Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| || | |EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| || | |Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | |Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| || | |Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| || | |Systemic chronic active EBV disease||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| || | |Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| || | ||
| | |Systemic EBV-Positive T-cell Lymphoma of Childhood | ||
| | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | ||
| | |Complete | ||
| | |11/21/2021 | ||
| | | | ||
|- | |- | ||